<DOC>
	<DOCNO>NCT00744926</DOCNO>
	<brief_summary>This 3 arm study ass efficacy , safety tolerability taspoglutide compare placebo patient type 2 diabetes mellitus inadequately control diet exercise . Patients randomize one 3 treatment arm : taspoglutide 10mg sc weekly , taspoglutide 20mg sc weekly ( 4 week taspoglutide 10mg sc weekly ) placebo . After first 24 week patient placebo switch taspoglutide 10mg weekly taspoglutide 20mg weekly ( 4 week taspoglutide 10mg weekly ) . The anticipated time study treatment 1 year , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Taspoglutide Versus Placebo Treatment Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet Exercise .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>adult patient , 1880 year age ; drug naive patient type 2 diabetes uncontrolled diet exercise ; test negative antiglutamic acid decarboxylase ( antiGAD ) antibodies ; Cpeptide ( fast ) &gt; =1.0ng/mL HbA1c &gt; =6.5 % &lt; =10.0 % screening ; BMI &gt; =25 ( &gt; 23 Asians ) &lt; =45kg/m2 screening ; stable weight +/ 5 % least 12 week prior screen . history type 1 diabetes mellitus acute metabolic diabetic complication ketoacidosis hyperosmolar coma previous 6 month ; evidence clinically significant diabetic complication ; symptomatic poorly control diabetes ; myocardial infarction , coronary artery bypass surgery , posttransplantation cardiomyopathy stroke within previous 6 month ; know hemoglobinopathy chronic anemia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>